Clinical Trial Update: Study Evaluating the Effect of R-mabHDI in Lymphocytic Predominant Hodgkin's Lymphoma [Phase 3]

View source ↗

Summary

This entry reports an ongoing Phase 3 clinical trial evaluating the monoclonal antibody R-mabHDI for Hodgkin lymphoma with a status listed as unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• R-mabHDI

Snippet

Sponsor: American Scitech International | Conditions: Hodgkin's Lymphoma | Phase 3 | Status: UNKNOWN